Edition:
United States

Masimo Corp (MASI.OQ)

MASI.OQ on NASDAQ Stock Exchange Global Select Market

86.61USD
18 Oct 2017
Change (% chg)

-- (--)
Prev Close
$86.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
186,743
52-wk High
$104.71
52-wk Low
$53.78

Chart for

About

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company's business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings... (more)

Overall

Beta: 0.75
Market Cap(Mil.): $4,440.88
Shares Outstanding(Mil.): 51.94
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.39 16.86
EPS (TTM): -- -- --
ROI: -- 13.79 11.22
ROE: -- 16.64 15.09

BRIEF-‍San Diego bankruptcy court issues final judgment on Masimo Corp

* Masimo Corp - ‍Bankruptcy court in San Diego has issued final judgment, holding that "Sotera Wireless employees misappropriated Masimo trade secrets"​ Source text for Eikon: Further company coverage:

Oct 16 2017

BRIEF-Masimo reports FDA clearance and full market release of rad-97 pulse co-oximeter

* Masimo announces FDA clearance and full market release of rad-97™ pulse co-oximeter® Source text for Eikon: Further company coverage:

Sep 18 2017

BRIEF-Masimo says CFO Mark De Raad to retire ‍​

* Masimo Corp - On August 23, Mark P. De Raad, CFO, notified co of his intention to retire and resign from his roles with the company‍​ ‍​

Aug 24 2017

BRIEF-Dubai Health Authority implementiert Masimo Patient SafetyNet

* Dubai Health Authority implementiert Masimo Patient SafetyNet Source text for Eikon: Further company coverage:

Aug 15 2017

BRIEF-Masimo Q2 earnings per share $0.83

* Q2 earnings per share view $0.71 -- Thomson Reuters I/B/E/S

Aug 02 2017

BRIEF-Masimo Corp says appears co addressed violations contained in FDA warning letter regarding Irvine facility

* Masimo - ‍on May 26, received letter from FDA indicating FDA has completed an evaluation of Masimo's corrective actions in response to warning letter​

Jun 06 2017

Earnings vs. Estimates